1. Medtech Insight
  2. >>Archive

Mouse Avatars: Innovative Approach Holds Promise For Personalizing Cancer Treatment

Champions Oncology has developed TumorGraft, a novel predictive chemo-response technology that allows companies to simulate clinical trials, test anticancer drug regimens, and identify the regimens most likely to positively impact individual cancer tumors. For the clinical trial simulation capabilities alone, the technology has a market potential of $1.6 billion in the US, according to the company.

Cancer is the second most common cause of death in the US, accounting for one of every four deaths and nearly 1,600 deaths per day in 2014 according to the American Cancer Society. While there are a plethora of chemotherapeutic drugs available to treat cancer, the genetic and epigenetic variability between the tumors of cancer patients creates significant challenges in accurately predicting which individuals will respond to a specific drug. Despite ongoing efforts to use genomic sequencing to improve patient response to chemotherapy, the personalization of oncology drugs remains limited. Furthermore, 83% of the $1.3 billion cost to successfully bring one drug through the FDA is spent on failed clinical trials due to the inability to predict the likelihood that patients will respond to new treatments.

To improve the success of cancer treatment and clinical trials, Hackensack, NJ-based Champions Oncology Inc. has developed TumorGraft technology,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Execs On The Move: July 14–18, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 
• By Amanda Maxwell

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

Medtech M&A Resurges: How To Define Startup Exit Strategy

 
• By Natasha Barrow

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.